论文部分内容阅读
目的回顾性分析利奈唑胺和万古霉素在治疗急性肾损伤患者耐甲氧西林金黄色葡萄球菌(MRSA)感染的临床疗效。方法分析苏州市立医院ICU2008年—2010年期间感染MRSA同时存在急性肾损伤(AKI)的危重患者44例,分别接受利奈唑胺和万古霉素治疗,分析其临床疗效和治疗过程中的安全性。结果利奈唑胺组临床有效率为80.0%,细菌清除率为80.0%,万古霉素组临床有效率为45.8%,细菌清除率为41.7%,两组比较差异有统计学意义(P<0.05)。因不良反应而停药的发生率两组比较无显著差异(P>0.05)。利奈唑胺组的死亡率(25.0%)低于万古霉素组(33.3%),差异无统计学意义(P>0.05)。结论对于急性肾损伤的患者MRSA感染利奈唑胺治疗的临床疗效优于万古霉素。
Objective To retrospectively analyze the clinical efficacy of linezolid and vancomycin in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with acute renal injury. Methods Forty-four critically ill patients with MRA and acute kidney injury (AKI) who were infected with MRSA from 2008 to 2010 in the ICU of Suzhou Municipal Hospital were treated with linezolid and vancomycin respectively. The clinical efficacy and safety during treatment were analyzed. Results The clinical effective rate was 80.0%, the bacterial clearance rate was 80.0% in the linezolid group, 45.8% in the vancomycin group and 41.7% in the vancomycin group, the difference was statistically significant (P <0.05) . The incidence of discontinuation due to adverse reactions was no significant difference between the two groups (P> 0.05). Linezolid group mortality (25.0%) was lower than the vancomycin group (33.3%), the difference was not statistically significant (P> 0.05). Conclusions The clinical efficacy of linezolid for MRSA infection in patients with acute kidney injury is superior to that of vancomycin.